Novel therapies for inflammation
ABCENTRA IS A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL ANTIBODY THERAPEUTICS FOR INFLAMMATORY DISEASES
Therapeutics that target oxLDL, a novel target and a specific a source of inflammation implicated in cardiovascular disease, rheumatic disease, and cancer.
By targeting oxLDL, safer alternatives to systemic anti-inflammatory treatments may be possible.
Lead candidate, orticumab, is being developed to treat atherosclerosis and plaque psoriasis.
Focused on clinical development of orticumab
for two indications:
Abcentra receives financial support from the European Union’s FP7 grant program Vaccine in Atherosclerosis (VIA)